In KRAS-mutant NSCLC patients, the most frequent additional genetic alterations are mutations in the TP53 gene (with a prevalence of 39–42%), STK11 gene (29–30%), Protein Tyrosine Phosphatase Receptor Type D (PTPRD) gene (15%), and Kelch-like ECH-associated protein 1/Nuclear Factor [Erythroid-derived 2]-like 2 (KEAP1/NFE2L2) gene (present in 24–27% of cases) [50,51]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.